GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Deferred Tax

Bausch & Lomb (TSX:BLCO) Deferred Tax : C$-11 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Bausch & Lomb's change in deferred tax for the three months ended in Dec. 2024 was C$40 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was C$-11 Mil.


Bausch & Lomb Deferred Tax Historical Data

The historical data trend for Bausch & Lomb's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Deferred Tax Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Deferred Tax
Get a 7-Day Free Trial 124.25 148.48 -122.27 -13.42 -14.25

Bausch & Lomb Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 59.56 32.89 -143.59 39.89

Bausch & Lomb Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-11 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bausch & Lomb Deferred Tax Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch & Lomb Business Description

Traded in Other Exchanges
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Executives
Ambrose Robert Douglas Bailey Senior Officer
Andrew Jude Stewart Senior Officer